BioNTech completes first in-house plasmid DNA manufacturing facility 02-Feb-2023 By Rachel Arthur mRNA pioneer BioNTech has completed construction of its first proprietary plasmid DNA manufacturing facility in Marburg, Germany.
Moderna’s vaccine combined with Keytruda reduced melanoma recurrence by 44%: ‘The results are highly encouraging for the field of cancer treatment’ 13-Dec-2022 By Jane Byrne Moderna and Merck, known as MSD outside the US and Canada, announced new data today showing the potential of mRNA-based personalized cancer vaccines.
Oncology vaccine ensured 100% survival rate in lab studies 18-Sep-2018 By Maggie Lynch Scientists demonstrated that an adjuvant to an immunotherapy vaccine resulted in a 100% survival rate in mice with aggressive melanoma.
Morphogenesis initiates first in-human clinical trial after working with companion animals 12-Sep-2018 By Maggie Lynch Morphogenesis launched its first in-human melanoma clinical study with Moffitt Cancer Center, as part of Moffitt’s Cutaneous Oncology Program.
